Jonathan I Epstein

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection
    Leander Van Neste
    MDxHealth, Irvine, CA, USA
    BMC Urol 12:16. 2012
  2. ncbi Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades
    Jonathan I Epstein
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
    Eur Urol 61:1019-24. 2012
  3. ncbi Diagnosis of limited adenocarcinoma of the prostate
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Histopathology 60:28-40. 2012
  4. ncbi Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy
    Cristina Magi-Galluzzi
    Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    Am J Surg Pathol 27:1128-33. 2003
  5. ncbi The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Medical Institutions, The Weinberg Building, 401 North Broadway, Room 2242, Baltimore, MD 21231, USA
    Crit Rev Oncol Hematol 47:83-9. 2003
  6. ncbi Prostatic ductal adenocarcinoma: a mini review
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Med Princ Pract 19:82-5. 2010
  7. ncbi Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Mod Pathol 17:307-15. 2004
  8. ncbi Precursor lesions to prostatic adenocarcinoma
    Jonathan I Epstein
    Departments of Pathology, Urology and Oncology, The Johns Hopkins Hospital, 401 N Broadway St, Rm 2242, Baltimore, MD, 21231, USA
    Virchows Arch 454:1-16. 2009
  9. ncbi Recommendations for the reporting of prostate carcinoma
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Pathol 38:1305-9. 2007
  10. ncbi The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Jonathan I Epstein
    Department of Pathology, Urology and Oncology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Am J Surg Pathol 29:1228-42. 2005

Detail Information

Publications113 found, 100 shown here

  1. ncbi A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection
    Leander Van Neste
    MDxHealth, Irvine, CA, USA
    BMC Urol 12:16. 2012
    ..The epigenetic states of these genes can be used to assess the likelihood of cancer presence or absence...
  2. ncbi Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades
    Jonathan I Epstein
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
    Eur Urol 61:1019-24. 2012
    ..Prior studies assessing the correlation of Gleason score (GS) at needle biopsy and corresponding radical prostatectomy (RP) predated the use of the modified Gleason scoring system and did not factor in tertiary grade patterns...
  3. ncbi Diagnosis of limited adenocarcinoma of the prostate
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Histopathology 60:28-40. 2012
    ..Some of the more common situations leading to an atypical diagnosis have also been presented to help prevent the overdiagnosis of prostatic malignancy...
  4. ncbi Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy
    Cristina Magi-Galluzzi
    Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    Am J Surg Pathol 27:1128-33. 2003
    ..It is important to optimize the staining technique for each laboratory and recognize that some small cancers on needle biopsy may be AMACR negative...
  5. ncbi The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Medical Institutions, The Weinberg Building, 401 North Broadway, Room 2242, Baltimore, MD 21231, USA
    Crit Rev Oncol Hematol 47:83-9. 2003
    ..Since its inception, several studies have been published documenting the relationship of tumors classified using the WHO/ISUP system to prognosis. These articles are summarized within this review...
  6. ncbi Prostatic ductal adenocarcinoma: a mini review
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Med Princ Pract 19:82-5. 2010
    ..Mimickers of ductal adenocarcinoma include prostatic urethral polyps, hyperplastic benign prostate glands, high-grade PIN, colorectal adenocarcinoma, and papillary urothelial carcinoma...
  7. ncbi Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Mod Pathol 17:307-15. 2004
    ..Finally, this paper will briefly cover the significance of atypical or suspicious prostate needle biopsies, and how to report the key diagnostic and prognostic information on needle biopsy...
  8. ncbi Precursor lesions to prostatic adenocarcinoma
    Jonathan I Epstein
    Departments of Pathology, Urology and Oncology, The Johns Hopkins Hospital, 401 N Broadway St, Rm 2242, Baltimore, MD, 21231, USA
    Virchows Arch 454:1-16. 2009
    ..Finally, intraductal carcinoma of the prostate, a controversial entity, is discussed and differentiated from high-grade PIN...
  9. ncbi Recommendations for the reporting of prostate carcinoma
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Pathol 38:1305-9. 2007
    ..However, ADASP hopes that pathologists will find these checklists useful in daily clinical practice while facilitating compliance with the new COC requirements...
  10. ncbi The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Jonathan I Epstein
    Department of Pathology, Urology and Oncology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Am J Surg Pathol 29:1228-42. 2005
  11. ncbi Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy
    Jonathan I Epstein
    Department of Pathology, Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Urology 66:356-60. 2005
    ..To determine whether potential candidates for watchful waiting have undersampling of more substantial cancer...
  12. ncbi An update of the Gleason grading system
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins University School of Medicine, The James Brady Urological Institute, The Johns Hospital, Baltimore, Maryland 21231, USA
    J Urol 183:433-40. 2010
    ..An update is provided of the Gleason grading system, which has evolved significantly since its initial description...
  13. ncbi Recommendations for the reporting of prostate carcinoma
    Jonathan I Epstein
    The Johns Hopkins Hospital, 401 N Broadway St, Rom 2242, Baltimore, MD 21231, USA
    Virchows Arch 451:751-6. 2007
  14. ncbi Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains
    Ecaterina F Tamas
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Am J Surg Pathol 31:390-7. 2007
    ..When interpreting CK stains for the detection of residual tumor cells, one should pay attention to the nature of the cells and not assume all CK staining cells are residual tumor cells...
  15. ncbi Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    J Urol 186:790-7. 2011
    ..This review addresses the controversies that persist relating to the prognosis and reporting of tumor volume in adenocarcinoma of the prostate...
  16. ncbi What's new in prostate cancer disease assessment in 2006?
    Jonathan I Epstein
    Departments of Disease, Urology, and Oncology, The Johns Hopkins Hospital, 401 N Broadway, Baltimore, MD 21231, USA
    Curr Opin Urol 16:146-51. 2006
    ..Issues relating to the disease are critical in the diagnosis, management, and prognostication of prostate cancer...
  17. ncbi Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care
    Jonathan I Epstein
    Department of Pathology, The Johns Hopkins University School of Medicine, The James Brady Urological Institute, The Johns Hospital, Baltimore, Maryland 21231, USA
    J Urol 175:820-34. 2006
    ..We identified information critical for patient treatment on prostate needle biopsies diagnosed with prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma...
  18. ncbi Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists
    Jonathan I Epstein
    Department of Pathology, Urology and Oncology, The Johns Hopkins Hospital, Weinberg Building Rm 2242, Baltimore, MD 21231, USA
    Adv Anat Pathol 13:57-9. 2006
    ..This article serves as a brief overview and summary of the proceedings that have been published in detail in recent literature...
  19. ncbi DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction
    Sumit Isharwal
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 73:1092-7. 2009
    ..To evaluate nuclear morphometric alterations and clinicopathologic features for organ- vs nonorgan-confined prostate carcinoma (PCa) prediction...
  20. ncbi Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer
    Masood A Khan
    Department of Urology, James Buchanan Brady Urological Institute and Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA
    Urology 62:866-71. 2003
    ....
  21. ncbi Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas
    Antoun Toubaji
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Mod Pathol 24:1511-20. 2011
    ..In summary, TMPRSS2-ERG fusion was not prognostic for recurrence after retropubic radical prostatectomy for clinically localized prostate cancer, although men with ERG gene copy number gain without fusion were twice more likely to recur...
  22. ncbi A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy
    Phillip M Pierorazio
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 185:1691-7. 2011
    ..We investigated outcomes in men with pT3b disease in the contemporary era...
  23. ncbi Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy
    Masood A Khan
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer 98:2583-91. 2003
    ..QNG solutions can serve as a new supplemental biomarker for accurate prediction of PCa progression at the time of surgery...
  24. ncbi TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma
    Roula Albadine
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Mod Pathol 22:1415-22. 2009
    ..Our finding of comparable rate of TMPRSS2-ERG fusion in minute adenocarcinomas may argue against its value as a marker of aggressive prostate carcinoma phenotype...
  25. ncbi Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Prostate 68:183-9. 2008
    ..We assessed the use of quantitative clinical and pathologic information to predict which patients would eventually require treatment for prostate cancer (CaP) in an expectant management (EM) cohort...
  26. ncbi Obesity and capsular incision at the time of open retropubic radical prostatectomy
    Stephen J Freedland
    The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21287 2101, USA
    J Urol 174:1798-801; discussion 1801. 2005
    ..Therefore, we examined the association between body mass index (BMI) and capsular incision at RP as a surrogate of a poor technical operation in men treated for prostate cancer by several high volume surgeons at a center of excellence...
  27. ncbi Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 2101, USA
    Urology 69:1095-101. 2007
    ..To update the 2001 "Partin tables" with a contemporary patient cohort and revised variable categorization, correcting for the effects of stage migration...
  28. ncbi Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis
    Robert W Veltri
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 68:1806-15. 2008
    ..Therefore, we evaluated the prognostic value of these parameters in 105 clinically localized PCa tumors with long-term follow-up after radical prostatectomy for progression-free survival (PFS)...
  29. ncbi Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy
    Eli Rosenbaum
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, John Hopkins School of Medicine, Baltimore, MD 21205 2196, USA
    Clin Cancer Res 11:8321-5. 2005
    ..To analyze the prognostic significance of six epigenetic biomarkers (APC, Cyclin D2, GSTP1, TIG1, Rassf1A, and RARbeta2 promoter hypermethylation) in a homogeneous group of prostate cancer patients, following radical prostatectomy alone...
  30. ncbi Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center
    Hiroshi Miyamoto
    Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA
    Arch Pathol Lab Med 134:1160-3. 2010
    ....
  31. ncbi Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy
    Ahmed Magheli
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 178:1311-5. 2007
    ....
  32. ncbi Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy
    Fadi Brimo
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
    Am J Surg Pathol 34:715-22. 2010
    ..This model accurately categorized 78% of clinically malignant and 100% of the clinically benign epithelioid AMLs with atypia...
  33. ncbi Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification
    Samson W Fine
    Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA
    J Urol 174:1976-80. 2005
    ..Thus, the diagnostic category of PUNLMP allowed 43.5% of patients in this series to avoid being labeled with "cancer" at a young age...
  34. ncbi Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10
    Patrick J Bastian
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer 107:1265-72. 2006
    ..Whereas multimodal therapy has often meant radiation plus hormonal therapy, newer possibilities for multimodal therapy exist such as surgery with neoadjuvant or adjuvant chemohormonal therapy or surgery with adjuvant radiation...
  35. ncbi Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment
    Angelo M De Marzo
    Department of Oncology, The Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21231 1000, USA
    J Cell Biochem 91:459-77. 2004
    ..We also present the implications of these changes for prostate cancer diagnosis, detection, prevention, and treatment...
  36. ncbi Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy
    Ahmed Magheli
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 178:1277-80; discussion 1280-1. 2007
    ..We investigated biochemical outcomes following radical prostatectomy across subclassifications of clinical stage T1 prostate cancer...
  37. ncbi Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy
    Sumit Isharwal
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Int J Cancer 123:2636-43. 2008
    ..Further, Her-2/neu expression and %DNA index may be used with clinicopathologic parameters for prediction of long-term prognosis in PCa...
  38. ncbi Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience
    H Ballentine Carter
    Department of Urology, The Johns Hopkins University School of Medicine and The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, UAS
    J Urol 178:2359-64; discussion 2364-5. 2007
    ..We updated our experience with a strategy of expectant treatment for men with stage T1c prostate cancer and evaluated predictors of disease intervention...
  39. ncbi PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract
    Roula Albadine
    Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
    Am J Surg Pathol 34:965-9. 2010
    ..We investigated the expression pattern of PAX8 in CDC and its utility, in combination with p63, in resolving the differential diagnosis of CDC versus upper tract urothelial carcinoma (UUC)...
  40. ncbi Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program
    Ashley E Ross
    Departments of Urology and Pathology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 28:2810-6. 2010
    ....
  41. ncbi Characteristics of positive surgical margins in robotic-assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center
    Roula Albadine
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Pathol 43:254-60. 2012
    ..Preoperative prostate-specific antigen density and number of positive surgical margin foci were the only independent predictors of biochemical recurrence...
  42. ncbi NKX3.1 as a marker of prostatic origin in metastatic tumors
    Bora Gurel
    Department of Pathology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Surg Pathol 34:1097-105. 2010
    ..1, along with other prostate-restricted markers, may prove to be a valuable adjunct to definitively determine prostatic origin in poorly differentiated metastatic carcinomas...
  43. ncbi Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years
    Stephen J Freedland
    Departments of Urology, and Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Clin Cancer Res 11:2883-8. 2005
    ..Whether the association between obesity and aggressive disease has changed as a result of these temporal changes is unclear...
  44. ncbi Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate
    Robert W Veltri
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 10:3465-73. 2004
    ..The nuclear structure information was combined with routine pathological findings to predict metastatic PCa progression and/or death...
  45. ncbi TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas
    Tamara L Lotan
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Mod Pathol 22:359-65. 2009
    ....
  46. ncbi An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011
    John B Eifler
    James Buchanan Brady Urological Institute and the Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    BJU Int 111:22-9. 2013
    ..To update the 2007 Partin tables in a contemporary patient population...
  47. ncbi AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy
    Eli Rosenbaum
    Department of Otolaryngology and Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Prostate 72:1133-9. 2012
    ..To evaluate the prognostic significance of six epigenetic biomarkers (AIM1, CDH1, KIF1A, MT1G, PAK3, and RBM6 promoter hypermethlation) in a homogeneous group of prostate cancer patients, following radical prostatectomy (RP)...
  48. ncbi Diffuse expression of PAX2 and PAX8 in the cystic epithelium of mixed epithelial stromal tumor, angiomyolipoma with epithelial cysts, and primary renal synovial sarcoma: evidence supporting renal tubular differentiation
    Matthew Karafin
    Department of Pathology, The Johns Hopkins Medical Institutions, 401 N Broadway, Baltimore, MD 21231 2410, USA
    Am J Surg Pathol 35:1264-73. 2011
    ..Whether this complex epithelium represents entrapped or neoplastic renal tubular epithelium remains an open question...
  49. ncbi Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases
    Ecaterina F Tamas
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Mod Pathol 20:828-34. 2007
    ..Given the association of lymphoepithelioma-like carcinoma with urothelial carcinoma in 47% of our cases and its propensity for multifocality, partial cystectomy would typically be ill advised for lymphoepithelioma-like carcinoma...
  50. ncbi Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy
    Michael Muntener
    Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Eur Urol 53:767-75; discussion 775-6. 2008
    ..The objective of this study was to evaluate the prognostic significance of these discrepancies with respect to outcomes following RP...
  51. ncbi Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program
    Jeffrey J Tosoian
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 183:534-8. 2010
    ..We assessed the relationship between PCA3 and prostate biopsy results in men in a surveillance program...
  52. ncbi DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme
    Sumit Isharwal
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    BJU Int 105:329-33. 2010
    ..Study Type - Prognosis (case series)Level of Evidence 4...
  53. ncbi Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy
    David J Hernandez
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Urology 72:172-6. 2008
    ..We determined the incidence of biochemical recurrence (BR), local recurrence (LR), distant metastasis (DM), and prostate cancer-specific mortality (PCSM) among this low-risk cohort...
  54. ncbi Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
    Masood A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Urol 170:2274-8. 2003
    ..Therefore, we determined whether biomarkers could be used to determine those in whom disease is likely to progress and thus those who require definitive therapy...
  55. ncbi Repeat prostate biopsies predict location of index cancer in an active surveillance cohort
    Kenneth S Tseng
    Department of Urology and Pathology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    BJU Int 108:1415-20. 2011
    ..To evaluate the ability of repeat prostate biopsies to determine the location of the index cancer for men on prostate cancer surveillance...
  56. ncbi The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted
    Phillip M Pierorazio
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 183:151-7. 2010
    ..We examined biochemical recurrence-free survival and cancer specific survival in men with a positive bladder neck margin...
  57. ncbi Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence
    Matthew B Gretzer
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 60:1034-9. 2002
    ..Furthermore, using a cutpoint of 50% of cancer in a single core of biopsy tissue, additional risk stratification is afforded to men with higher risk "T1cII" cancer...
  58. ncbi ERG gene rearrangements are common in prostatic small cell carcinomas
    Tamara L Lotan
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Mod Pathol 24:820-8. 2011
    ..Finally, the absence of ERG rearrangement in bladder or lung small cell carcinomas highlights the utility of detecting ERG rearrangement in small cell carcinomas of unknown primary for establishing prostatic origin...
  59. ncbi Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer
    Ming Zhou
    Department of Pathology, John Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Am J Surg Pathol 27:772-8. 2003
    ..The major caveat in the interpretation of positive staining is that high-grade prostatic intraepithelial neoplasia cannot be in the differential diagnosis...
  60. ncbi Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination
    Toyonori Tsuzuki
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    J Urol 173:450-3. 2005
    ..Our algorithm will help provide objective parameters that aid in the decision to spare the NVB safely...
  61. ncbi Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion
    Mehsati Herawi
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Surg Pathol 29:874-80. 2005
    ..Negative or patchy staining for basal cells and positive staining for AMACR may contribute to diagnostic difficulty in these entities...
  62. ncbi Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney
    Samson W Fine
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 30:1554-60. 2006
    ..Pathologists must be aware of the spectrum of histologic findings within MTSCs to ensure their accurate diagnosis...
  63. ncbi Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml
    Danil V Makarov
    James Buchanan Brady Urological Institute, and the Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 176:554-8. 2006
    ..5 ng/ml as opposed to the more traditional greater than 4.0 ng/ml. We compared outcomes between men with clinical stage T1c disease undergoing radical prostatectomy who had a low vs slightly increased prostate specific antigen...
  64. ncbi Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate
    Mark L Gonzalgo
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 67:115-9. 2006
    ..To examine the relationship among needle biopsy primary grade, prostatectomy grade, and postprostatectomy biochemical recurrence among men with Gleason score 7 disease...
  65. ncbi Spindle cell lesions of the adult prostate
    Donna E Hansel
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Mod Pathol 20:148-58. 2007
    ..This review addresses the various entities that may present as spindle cell tumors within the adult prostate and discusses the functional aspects of the differential diagnosis of these lesions...
  66. ncbi Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance
    Charles C Guo
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mod Pathol 19:1528-35. 2006
    ..Consideration should be given to treat patients with IDC-P on biopsy aggressively even in the absence of documented infiltrating cancer...
  67. ncbi Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability
    H Ballentine Carter
    Department of Urology, Marburg 403, Johns Hopkins School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA
    J Natl Cancer Inst 98:1521-7. 2006
    ..The rate at which serum PSA levels change (PSA velocity) may be an important indicator of the presence of life-threatening disease...
  68. ncbi Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men
    Lori J Sokoll
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Urology 60:18-23. 2002
    ..985). In summary, cPSA was equivalent to total PSA in predicting organ-confined disease. Present and future models and nomograms using PSA as an indicator of pathological stage could consider use of cPSA...
  69. ncbi Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: report of 72 cases with clinical follow-up
    Jeremy S Miller
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    BJU Int 106:330-3. 2010
    ..To describe the histological findings and prognosis that are associated with extraprostatic extension (EPE) on needle core biopsy of prostatic adenocarcinoma...
  70. ncbi Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma
    Elizabeth A Montgomery
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Am J Surg Pathol 30:1502-12. 2006
    ..For these reasons, close follow-up is warranted...
  71. ncbi Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease
    Stephen J Freedland
    James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287-2101, USA
    Urology 63:887-91. 2004
    ....
  72. ncbi Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
    Barnett S Kramer
    National Institutes of Health, Bethesda, MD, USA
    J Urol 181:1642-57. 2009
    ..To develop an evidence-based guideline on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention...
  73. ncbi Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer
    Jeffrey T Schowinsky
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Am J Surg Pathol 30:866-70. 2006
    ..Recognition of these features mimicking prostate cancer and awareness of other findings that are diagnostic of rectal tissue on biopsy can prevent a misdiagnosis of atypical prostate glands or prostate cancer...
  74. ncbi Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge
    Robert W Veltri
    Brady Urological Institute of The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2101, USA
    J Urol 168:100-4. 2002
    ..4%. CONCLUSIONS: The quantitative nuclear grade biomarker was the strongest independent predictor of pathological stage in men with clinical stage T1c prostate cancer when combined with biopsy Gleason score and complexed PSA density data...
  75. ncbi Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy
    Sheldon Bastacky
    Department of Pathology, University of Pittsburgh School of Medicine, PA, USA
    Hum Pathol 35:281-9. 2004
    ....
  76. ncbi Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003
    Masood A Khan
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Urology 62:86-91; discussion 91-2. 2003
    ..Younger men also demonstrate greater long-term cancer control rates than older men...
  77. ncbi Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy
    Charles R Pound
    James Buchanan Brady Urological Institute and Department of Pathology, Johns Hopkins University Medical Institutions, Baltimore, Maryland 21287, USA
    Urology 59:85-90. 2002
    ..62). CONCLUSIONS: We were unable to show that PNI on needle biopsy influences long-term tumor-free survival...
  78. ncbi High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases
    Fabio Tavora
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Am J Surg Pathol 32:1060-7. 2008
    ..Recognition of this entity is critical to differentiate it from both HGPIN and conventional ductal adenocarcinoma...
  79. ncbi Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Danil V Makarov
    Department of Pathology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 167:2440-2. 2002
    ..This practice would remove a source of poor interobserver reproducibility when grading prostate cancer on needle biopsy...
  80. ncbi Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma
    Alexander Haese
    Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins University Medical Institution, Baltimore, Maryland 21287, USA
    Cancer 95:1016-21. 2002
    ..The algorithm was applied to sextant biopsy material and radical retropubic prostatectomy (RRP) stage obtained from a cohort of men who were treated at the authors' institution...
  81. ncbi Negative 34betaE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases
    Marc K Halushka
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Hum Pathol 35:43-6. 2004
    ..In a small focus of atypical glands on prostate biopsy, negative staining for 34betaE12 should not necessarily lead to a definitive malignant diagnosis in all cases, because almost half of these biopsies on follow-up sampling are benign...
  82. ncbi Fragmentation of prostatic needle biopsy cores containing adenocarcinoma: the role of specimen submission
    Daniel A Fajardo
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA
    BJU Int 105:172-5. 2010
    ..To determine the factors contributing to the fragmentation of prostatic core biopsies containing prostatic carcinoma, which might complicate the quantification of the number cores with cancer and/or the amount of tumour in a core...
  83. ncbi Threshold for diagnosing prostate cancer over time
    Cristina Magi-Galluzzi
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    Hum Pathol 34:1116-8. 2003
    ..It appears that pathologists are becoming more skilled at diagnosing limited prostate cancer and are referring predominantly cases with fewer cancer glands and more difficult atypical cases with few glands...
  84. ncbi Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density
    Robert W Allan
    Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    J Urol 170:370-2. 2003
    ..PSAD may have some value within this group in guiding clinicians and patients as to the likelihood of having clinically insignificant tumors...
  85. ncbi How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?
    Ming Zhou
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Surg Pathol 28:239-43. 2004
    ..However, it is not known how often a positive AMACR staining is used merely to support a malignant diagnosis that could otherwise be established based on routine H&E histology and negative basal cell staining...
  86. ncbi Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases
    Adeboye O Osunkoya
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Am J Surg Pathol 31:1323-9. 2007
    ....
  87. ncbi The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate
    Todd Sheridan
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231 2401, USA
    Am J Surg Pathol 31:1351-5. 2007
    ..Owing to its apparent specificity, prostein may be a good marker to demonstrate prostatic origin in metastatic prostate cancer...
  88. ncbi Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  89. ncbi Characterization of minute adenocarcinomas of prostate at radical prostatectomy
    Alexander M Truskinovsky
    Department of Pathology, University of California, Davis, Medical Center, Sacramento, California, USA
    Urology 64:733-7. 2004
    ..Patients with the above clinical and biopsy findings should be counseled about the possibility of finding only minute foci of carcinoma at radical prostatectomy and may want to consider watchful waiting...
  90. ncbi Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases
    Adeboye O Osunkoya
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Am J Surg Pathol 32:461-7. 2008
    ..Pathologists need to be aware of this rare and unusual phenomenon, which is a potential pitfall in prostate cancer diagnosis...
  91. ncbi High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases
    Jin Zhao
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Am J Surg Pathol 33:583-90. 2009
    ..A unique subset of high-grade foamy gland carcinoma poses particularly difficult diagnostic challenges, with scattered, scant, relatively bland foamy glands imbedded in an extensive densely sclerotic desmoplastic stroma...
  92. ncbi Diffuse adenosis of the peripheral zone in prostate needle biopsy and prostatectomy specimens
    Tamara L Lotan
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Am J Surg Pathol 32:1360-6. 2008
    ..Our findings suggest that DAPZ should be considered a risk factor for prostate cancer and that patients with this finding should be followed closely and rebiopsied...
  93. ncbi Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma
    Nathalie C Rioux-Leclercq
    Department ofUrology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Urology 60:666-9. 2002
    ....
  94. ncbi Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody
    Bahram R Oliai
    Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Am J Surg Pathol 26:1151-60. 2002
    ..The diagnosis of PCa in the face of positive 34betaE12 basal cell staining should be made with extreme caution, only in the face of unequivocal cancer on the hematoxylin and eosin stain...
  95. ncbi Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies
    Gregory A Hosler
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Hum Pathol 36:480-5. 2005
    ..Immunohistochemistry can be useful for documenting the basal cell layer and demonstrating negative racemase staining...
  96. ncbi Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study
    Wenle Wang
    Department of Pathology, The John Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Am J Surg Pathol 32:851-7. 2008
    ..Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma...
  97. ncbi Lesions missed on prostate biopsies in cases sent in for consultation
    Joseph D Kronz
    The Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Prostate 54:310-4. 2003
    ..Although our incidence of missed lesions gives some indication as to the magnitude of the problem, it cannot be equated with the risk of missing lesions in unselected cases...
  98. ncbi Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma
    Susan V Harden
    Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Division, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Urol 169:1138-42. 2003
    ..It represents a promising diagnostic marker that could be used as an adjunct to tissue biopsy as part of prostate cancer screening...
  99. ncbi The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy
    Fadi Brimo
    Department of Pathology, The Johns Hopkins Hospital Medical Institutions, Baltimore, Maryland, USA
    J Urol 184:126-30. 2010
    ..We determined the value of mandatory second opinion pathology review to interpret prostate needle biopsy before radical prostatectomy...
  100. ncbi Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
    Theresa Y Chan
    Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    Urology 62:177-81. 2003
    ..Therefore, pro-PSA may be a useful marker in differentiating high-grade prostate adenocarcinoma from other non-prostate carcinomas...
  101. ncbi Risk stratification of men choosing surveillance for low risk prostate cancer
    Kenneth S Tseng
    Department of Urology, The Johns Hopkins University School of Medicine and The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    J Urol 183:1779-85. 2010
    ..We sought to predict biopsy progression in men on prostate cancer surveillance...